[The efficacy of ethylmethylhydroxypyridine in the rehabilitation treatment of poststroke patients]. / Effektivnost' primeneniya etilmetilgidroksipiridina suktsinata v vosstanovitel'nom lechenii patsientov, perenesshikh ishemicheskii insul't.

The analysis of the clinical efficacy and safety of ethylmethylhydroxypyridine succinate (mexidol) in the complex of rehabilitation measures in patients after ischemic stroke (IS) shows that course treatment with mexidol improves the recovery of neurological functions, decreases neurological deficit, cognitive disorders, including memory impairment, and manifestations of asthenic syndrome, increases the level of social adaptation and improves the psycho-emotional state of patients, reduces spasticity, increases motor and speech activity, praxis, reliably eliminates the ignoring syndrome. There is a decrease in the level of total cholesterol and low-density b-lipoproteins in the blood, and decrease in the severity of hypercoagulation. The results of the studies have convincingly shown the efficacy of mexidol at all stages of rehabilitation treatment of patients with IS.

[Present-day therapeutic policy in patients with chronic ischaemia of lower limbs: trans-Atlantic inter-society consensus].

The authors have reviewed the available literature dedicated to the development of the treatment policy for managing the patients presenting with lower limb ischaemia. Central to the work is the analysis of the latest guidelines on therapeutic policy to pursue in patients presenting with chronic ischemia of the lower extremities, namely the Trans-Atlantic Inter-Society Consensus Document. This is followed by a detailed discussion of the indications for surgical and endovascular operative interventions in various-type lesions of the aortofemoral and femoropopliteal segments. Summarized herein are the main trends and tendencies in the present-day strategy of managing the patient cohort concerned.

The use angiogenesis stimulators for the treatment of chronic ischemia of lower extremities.

We present the results of treatment of chronic ischemia of the lower extremities (distal form) with angiogenesis stimulators, autologous endothelioblast precursors (CD133+) and gene preparation of vascular endothelial growth factor VEGF165 (angiostimulin). Good clinical effect was attained in all patients, which was confirmed instrumentally 1, 3, and 6 months after administration of the stimulant: transcutaneous oxygen tension on the foot, index of malleolar pressure, and walking duration increased, parameters of microcirculation improved, the number of newly formed collateral arteries increased (angiography findings), quality of life improved (SF 36 questionnaire), and parameters of coagulogram also improved. The maximum positive dynamics was observed by month 3 of the study.